Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Immunocore Holdings (IMCR) Other Non Operating Income (2020 - 2026)

Immunocore Holdings' Other Non Operating Income history spans 6 years, with the latest figure at $4.5 million for Q4 2025.

  • On a quarterly basis, Other Non Operating Income rose 353.58% to $4.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $14.3 million, a 600.15% increase, with the full-year FY2025 number at $19.7 million, up 38.95% from a year prior.
  • Other Non Operating Income hit $4.5 million in Q4 2025 for Immunocore Holdings, down from $5.1 million in the prior quarter.
  • Over the last five years, Other Non Operating Income for IMCR hit a ceiling of $11.2 million in Q3 2023 and a floor of -$12.5 million in Q4 2023.
  • Historically, Other Non Operating Income has averaged -$83111.9 across 5 years, with a median of -$190000.0 in 2023.
  • Biggest five-year swings in Other Non Operating Income: plummeted 3792.04% in 2022 and later surged 651.58% in 2023.
  • Tracing IMCR's Other Non Operating Income over 5 years: stood at -$7.6 million in 2021, then soared by 73.34% to -$2.0 million in 2022, then crashed by 514.5% to -$12.5 million in 2023, then skyrocketed by 107.93% to $993000.0 in 2024, then soared by 353.58% to $4.5 million in 2025.
  • Business Quant data shows Other Non Operating Income for IMCR at $4.5 million in Q4 2025, $5.1 million in Q3 2025, and -$738000.0 in Q2 2025.